National Asset Management Inc. Has $13.67 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

National Asset Management Inc. lifted its stake in Johnson & Johnson (NYSE:JNJ) by 20.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 92,755 shares of the company’s stock after acquiring an additional 16,035 shares during the period. Johnson & Johnson makes up 0.7% of National Asset Management Inc.’s portfolio, making the stock its 25th largest holding. National Asset Management Inc.’s holdings in Johnson & Johnson were worth $13,667,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in JNJ. BlackRock Inc. boosted its stake in Johnson & Johnson by 0.6% during the second quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock worth $27,242,005,000 after buying an additional 1,168,129 shares in the last quarter. Morgan Stanley boosted its stake in Johnson & Johnson by 0.3% during the first quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock worth $2,727,694,000 after buying an additional 54,563 shares in the last quarter. Nordea Investment Management AB boosted its stake in Johnson & Johnson by 88.0% during the second quarter. Nordea Investment Management AB now owns 17,222,162 shares of the company’s stock worth $2,382,514,000 after buying an additional 8,062,204 shares in the last quarter. Swiss National Bank boosted its stake in Johnson & Johnson by 1.4% during the second quarter. Swiss National Bank now owns 11,304,866 shares of the company’s stock worth $1,589,803,000 after buying an additional 157,100 shares in the last quarter. Finally, California Public Employees Retirement System boosted its stake in Johnson & Johnson by 8.9% during the third quarter. California Public Employees Retirement System now owns 10,616,780 shares of the company’s stock worth $1,580,626,000 after buying an additional 864,547 shares in the last quarter. Institutional investors and hedge funds own 67.44% of the company’s stock.

A number of equities research analysts have weighed in on JNJ shares. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Cantor Fitzgerald lifted their price target on shares of Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. Credit Suisse Group lifted their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a report on Wednesday, October 14th. Raymond James reissued a “buy” rating on shares of Johnson & Johnson in a report on Friday. Finally, Stifel Nicolaus cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company. Johnson & Johnson presently has an average rating of “Buy” and a consensus price target of $164.93.

In related news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the transaction, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.27% of the company’s stock.

Johnson & Johnson stock opened at $146.36 on Friday. The stock has a 50-day simple moving average of $145.51 and a 200 day simple moving average of $146.57. The company has a quick ratio of 1.24, a current ratio of 1.48 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $157.00. The stock has a market capitalization of $385.30 billion, a price-to-earnings ratio of 23.01, a P/E/G ratio of 3.04 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The business had revenue of $21.08 billion during the quarter, compared to analysts’ expectations of $20.15 billion. During the same period in the previous year, the business posted $2.12 earnings per share. The firm’s revenue for the quarter was up 1.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson & Johnson will post 7.99 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.01 dividend. The ex-dividend date of this dividend is Monday, November 23rd. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.76%. Johnson & Johnson’s dividend payout ratio is 46.54%.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Story: What is Liquidity?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.